Safety and efficacy of intensive vs. guideline antiplatelet therapy in high‐risk patients with recent ischemic stroke or transient ischemic attack: rationale and design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial (ISRCTN47823388)

RATIONALE: The risk of recurrence following a stroke or transient ischemic attack is high, especially immediately after the event. HYPOTHESIS: Because two antiplatelet agents are superior to one in patients with non‐cardioembolic events, more intensive treatment might be even more effective. SAMPLE...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Protocols
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855643/
https://www.ncbi.nlm.nih.gov/pubmed/26079743
http://dx.doi.org/10.1111/ijs.12538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855643/
https://www.ncbi.nlm.nih.gov/pubmed/26079743
http://dx.doi.org/10.1111/ijs.12538

Ejemplares similares